Baxter reports financial results

07/22/2010 | Wall Street Journal, The

Baxter International reported a decrease in earnings for the second quarter, owing to economic and product issues. The company expects sales of its plasma protein and antibody therapy products to decline for the rest of the year because of continued market issues. It also said it has stepped up its strategies to strengthen sales of Gammagard, a plasma-based drug.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Director of ASO Department
Bluegrass Family Health
Lexington-or could be in Nashville, TN, KY
Claims Director
PacificSource
Springfield, OR
Mgr NGS Provider Enrollment (I)
National Government Services - WellPoint
Harrisburg, PA
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA